Toronto, Ontario Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

Toronto, Ontario--(Newsfile Corp. - October 4, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, provides the following update for its AcuVidTM Covid-19 Rapid Saliva Antigen Test.

  • Therma Bright filed its application for EUA approval to market its AcuVid™ Covid-19 Rapid Antigen Saliva Test with the US FDA on as previously reported on July 22nd and September 1st, 2021. Therma continues to monitor and interact with the US FDA as necessary regarding our active submission.
  • Therma Bright has ordered sufficient materials and components to manufacture the first batch of AcuVid™ tests in the US. At the same time, Therma is securing multiple manufacturing sites in different countries to be able to meet the anticipated demand for our test in the US and elsewhere.
  • Therma is identifying and negotiating with potential customers in various jurisdictions to secure initial orders pending regulatory approval.
  • In September the Centers for Disease Control and Prevention (CDC) stated that they expect shortages of rapid tests as demand increases. The CDC, and other bodies, recommend serial testing using rapid antigen tests at least once per week, along with other mitigation measures, such as masking and social distancing, to reduce disease transmission, especially in congregant settings such as workplaces, schools and large events.
  • Therma is currently identifying sites to perform trials on the AcuVid™ test for home use applications. The results from these trials will be used to file for approval to market the AcuVid™ Covid-19 Rapid Antigen Saliva Test for home use by non-healthcare professionals. This should greatly expand the market for our test. Once a site is identified, Therma expects to report back to shareholders on the expected date to complete the home use clinical study.

Rob Fia, CEO of Therma Bright, commented, "We continue to build manufacturing capacity for our test in anticipation of approval so that we can meet the expected huge demand for rapid testing. Our saliva-based test is easier to use and less intrusive than nasal swab-based tests and is ideally suited for rapid testing for all subjects."

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the US FDA in 1997 for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings.

Therma Bright Inc. trades on the TSXV: THRM, OTCQB: TBRIF, FSE: JNX. For more information visit: and

For further information, please contact:

Therma Bright Inc.
Rob Fia, CEO
[email protected]

Follow us on Twitter


Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation, regulatory applications and manufacturing scale up as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Corporate Logo

To view the source version of this press release, please visit

This content was first published by KISS PR Brand Story. Read here >> Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test